Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroparesis
Conditions
Gastroparesis, Opioid Use
Trial Timeline
Dec 29, 2016 → Sep 30, 2019
NCT ID
NCT03036891About Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet
Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet is a phase 2 stage product being developed by AstraZeneca for Gastroparesis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03036891. Target conditions include Gastroparesis, Opioid Use.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03036891 | Phase 2 | Withdrawn |
Competing Products
19 competing products in Gastroparesis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 2 | 52 |
| Granisetron | Kyowa Kirin | Phase 2 | 52 |
| tadalafil | Eli Lilly | Approved | 85 |
| Mosapride + domperidone | Sumitomo Pharma | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Sitagliptin + Placebo | Merck | Phase 1 | 33 |
| Tegaserod | Novartis | Approved | 85 |
| Reglan ODT | UCB | Pre-clinical | 20 |
| Hemin + Albumin | Recordati | Phase 2 | 49 |
| CNSA-001 + Placebo | PTC Therapeutics | Phase 2 | 49 |
| Immediate-release omeprazole + Delayed-release omeprazole | Bausch Health | Approved | 80 |
| Velusetrag + Placebo | Theravance Biopharma | Phase 2 | 47 |
| velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo | Theravance Biopharma | Phase 2 | 47 |
| IW-9179 + Matching Placebo | Ironwood Pharmaceuticals | Phase 2 | 44 |
| VLY-686 (Tradipitant) | Vanda Pharmaceuticals | Phase 2 | 44 |
| Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |
| Tradipitant | Vanda Pharmaceuticals | Pre-clinical | 15 |
| Tradipitant + Placebo + Open Label Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |